VIVUS Stock Price, News & Analysis (NASDAQ:VVUS)

$0.48 0.00 (0.00 %)
(As of 01/24/2018 04:39 AM ET)
Previous Close$0.48
Today's Range$0.47 - $0.49
52-Week Range$0.45 - $1.38
Volume276,100 shs
Average Volume488,160 shs
Market Capitalization$50.89 million
P/E Ratio1.45
Dividend YieldN/A
Beta0.8

About VIVUS (NASDAQ:VVUS)

VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:VVUS
CUSIP92855110
Phone+1-650-9345200

Debt

Debt-to-Equity Ratio643.86%
Current Ratio7.47%
Quick Ratio7.09%

Price-To-Earnings

Trailing P/E Ratio1.45454545454545
Forward P/E Ratio-1.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$124.26 million
Price / Sales0.41
Cash Flow$0.42 per share
Price / Cash1.13
Book Value$0.17 per share
Price / Book2.82

Profitability

Trailing EPS$0.33
Net Income$23.30 million
Net Margins26.71%
Return on Equity344.23%
Return on Assets12.56%

Miscellaneous

Employees65
Outstanding Shares105,950,000

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The biopharmaceutical company had revenue of $15.19 million for the quarter, compared to analyst estimates of $16 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. VIVUS's quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) EPS. View VIVUS's Earnings History.

When will VIVUS make its next earnings announcement?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for VIVUS.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:

  • David York Norton, Independent Chairman of the Board (Age 66)
  • Thomas B. King, Interim Chief Executive Officer, Director (Age 63)
  • Mark K. Oki CPA, Chief Financial Officer, Chief Accounting Officer (Age 48)
  • John L. Slebir Esq., Senior Vice President - Business Development, General Counsel, Secretary (Age 50)
  • Santosh T. Varghese M.D., Chief Medical Officer (Age 47)
  • Jorge Plutzky M.D., Independent Director (Age 57)
  • Eric W. Roberts, Independent Director (Age 53)
  • Herman Rosenman CPA, Independent Director (Age 70)
  • Allan L. Shaw, Independent Director (Age 53)

Who owns VIVUS stock?

VIVUS's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.53%) and Creative Planning (0.35%). Company insiders that own VIVUS stock include North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.

Who sold VIVUS stock? Who is selling VIVUS stock?

VIVUS's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Company insiders that have sold VIVUS company stock in the last year include North Tide Capital, Llc and Santosh T Varghese. View Insider Buying and Selling for VIVUS.

Who bought VIVUS stock? Who is buying VIVUS stock?

VIVUS's stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for VIVUS.

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VIVUS stock can currently be purchased for approximately $0.48.

How big of a company is VIVUS?

VIVUS has a market capitalization of $50.89 million and generates $124.26 million in revenue each year. The biopharmaceutical company earns $23.30 million in net income (profit) each year or $0.33 on an earnings per share basis. VIVUS employs 65 workers across the globe.

How can I contact VIVUS?

VIVUS's mailing address is 900 E Hamilton Ave Ste 550, CAMPBELL, CA 95008-0643, United States. The biopharmaceutical company can be reached via phone at +1-650-9345200 or via email at [email protected]


MarketBeat Community Rating for VIVUS (VVUS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  519
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

VIVUS (NASDAQ:VVUS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

VIVUS (NASDAQ:VVUS) Consensus Price Target History

Price Target History for VIVUS (NASDAQ:VVUS)

VIVUS (NASDAQ:VVUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/29/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00N/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

VIVUS (NASDAQ:VVUS) Earnings History and Estimates Chart

Earnings by Quarter for VIVUS (NASDAQ:VVUS)

VIVUS (NASDAQ VVUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.13)N/AView Earnings Details
11/7/2017Q3 2017($0.13)($0.06)$16.00 million$15.19 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$11.23 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.27)($0.22)ViewN/AView Earnings Details
8/2/2010Q2 2010($0.23)($0.28)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.26)($0.23)ViewN/AView Earnings Details
3/8/2010Q4 2009($0.25)($0.16)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.31)($0.30)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.18)($0.19)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.08)($0.10)ViewN/AView Earnings Details
3/9/2009Q4 2008($0.05)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.05)$0.06ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08($0.12)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.21$0.17ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

VIVUS (NASDAQ:VVUS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS

Dividends

Dividend History for VIVUS (NASDAQ:VVUS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

VIVUS (NASDAQ VVUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 31.33%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

VIVUS (NASDAQ VVUS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/1/2018Santosh T VargheseInsiderSell444$0.51$226.4472,296View SEC Filing  
10/3/2017Santosh T VargheseInsiderSell434$0.97$420.98View SEC Filing  
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.2973,174View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.2073,597View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.1974,037View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.8074,830View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.4088,610View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.1388,966View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86101,525View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85101,891View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.9244,555View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.603,080View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

VIVUS (NASDAQ VVUS) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPSZacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - January 22 at 11:30 AM
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUSFree Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS
www.bizjournals.com - January 17 at 10:30 AM
VIVUS (VVUS) Rating Lowered to Hold at Zacks Investment ResearchVIVUS (VVUS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 1:16 PM
-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter
www.americanbankingnews.com - January 5 at 11:36 AM
VIVUS (VVUS) Announces Thomas King as Interim CEO - StreetInsider.comVIVUS (VVUS) Announces Thomas King as Interim CEO - StreetInsider.com
www.streetinsider.com - December 27 at 6:16 PM
ETFs with exposure to VIVUS, Inc. : December 22, 2017ETFs with exposure to VIVUS, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 6:25 PM
ETFs with exposure to VIVUS, Inc. : December 11, 2017ETFs with exposure to VIVUS, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:29 PM
Pre-Market Technical Scan on Biotech Equities -- Regeneron Pharma, Voyager Therapeutics, Five Prime Therapeutics ... - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Regeneron Pharma, Voyager Therapeutics, Five Prime Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - December 5 at 12:20 PM
VIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngineVIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 1 at 11:52 PM
ETFs with exposure to VIVUS, Inc. : November 20, 2017ETFs with exposure to VIVUS, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 4:02 PM
 Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - November 17 at 1:38 PM
ETFs with exposure to VIVUS, Inc. : November 10, 2017ETFs with exposure to VIVUS, Inc. : November 10, 2017
finance.yahoo.com - November 12 at 1:16 PM
Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:43 AM
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 9:43 AM
VIVUS, Inc. (VVUS) Releases  Earnings Results, Beats Estimates By $0.07 EPSVIVUS, Inc. (VVUS) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Vivus reports 3Q lossVivus reports 3Q loss
finance.yahoo.com - November 7 at 6:25 PM
VIVUS Reports Third Quarter 2017 Financial ResultsVIVUS Reports Third Quarter 2017 Financial Results
feeds.benzinga.com - November 7 at 4:43 PM
VIVUS, Inc. to Host Earnings CallVIVUS, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 1:24 PM
VIVUS Completes Tacrolimus Pre-IND Meeting With FDAVIVUS Completes Tacrolimus Pre-IND Meeting With FDA
finance.yahoo.com - November 2 at 11:13 AM
ETFs with exposure to VIVUS, Inc. : October 30, 2017ETFs with exposure to VIVUS, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 12:01 PM
VIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on TuesdayVIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
feeds.benzinga.com - October 31 at 8:50 AM
ETFs with exposure to VIVUS, Inc. : October 20, 2017ETFs with exposure to VIVUS, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 4:34 PM
Financial Review: VIVUS (VVUS) vs. The CompetitionFinancial Review: VIVUS (VVUS) vs. The Competition
www.americanbankingnews.com - October 17 at 8:26 AM
VIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head ReviewVIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head Review
www.americanbankingnews.com - October 12 at 10:32 PM
ETFs with exposure to VIVUS, Inc. : October 9, 2017ETFs with exposure to VIVUS, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 8:14 AM
Critical Contrast: VIVUS (VVUS) versus Its PeersCritical Contrast: VIVUS (VVUS) versus Its Peers
www.americanbankingnews.com - October 9 at 6:28 PM
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 12:42 PM
Argos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head SurveyArgos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head Survey
www.americanbankingnews.com - September 29 at 12:34 PM
Orexigens (OREX) Contrave Sales Improving on PromotionsOrexigen's (OREX) Contrave Sales Improving on Promotions
www.zacks.com - September 28 at 10:20 AM
Critical Survey: VIVUS (VVUS) versus Its RivalsCritical Survey: VIVUS (VVUS) versus Its Rivals
www.americanbankingnews.com - September 18 at 2:26 AM
VIVUS, Inc. (VVUS) Sees Large Drop in Short InterestVIVUS, Inc. (VVUS) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 15 at 1:28 AM
VIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAHVIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH
www.streetinsider.com - September 8 at 10:10 AM
VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline AnalysisVIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis
finance.yahoo.com - September 8 at 10:10 AM
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial HypertensionVIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - September 7 at 11:05 AM
VIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - StreetInsider.comVIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - StreetInsider.com
www.streetinsider.com - September 6 at 10:09 AM
VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of KoreaVIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
finance.yahoo.com - September 6 at 10:09 AM
VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 4 at 3:41 PM
VIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head SurveyVIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head Survey
www.americanbankingnews.com - September 2 at 10:24 PM
VIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per ShareVIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 2 at 2:26 AM
VIVUS (VVUS) Settles with Dr. Reddys Laboratories on Qsymia ... - StreetInsider.comVIVUS (VVUS) Settles with Dr. Reddy's Laboratories on Qsymia ... - StreetInsider.com
www.streetinsider.com - August 31 at 1:57 AM
VIVUS Announces Settlement with Dr. Reddys Laboratories on Qsymia(R) Patent LitigationVIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
finance.yahoo.com - August 30 at 8:54 PM
Vivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking AlphaVivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking Alpha
seekingalpha.com - August 23 at 1:46 PM
VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
finance.yahoo.com - August 23 at 1:46 PM
Critical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS)Critical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - August 19 at 8:44 AM
Vivus Pipeline Review, Analysis and Potential CatalystsVivus Pipeline Review, Analysis and Potential Catalysts
finance.yahoo.com - August 10 at 9:34 AM
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - NasdaqVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - Nasdaq
www.nasdaq.com - August 9 at 8:59 AM
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/YVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
finance.yahoo.com - August 8 at 8:15 AM
Peregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head AnalysisPeregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head Analysis
www.americanbankingnews.com - August 5 at 8:36 PM
VIVUS Reports Second Quarter 2017 Financial ResultsVIVUS Reports Second Quarter 2017 Financial Results
feeds.benzinga.com - August 3 at 4:34 PM

SEC Filings

VIVUS (NASDAQ:VVUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

VIVUS (NASDAQ:VVUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

VIVUS (NASDAQ VVUS) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.